Silicon Dioxide
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Silicon Dioxide: From Pharmaceutical Excipient to Active Peptic Ulcer Disease
One-Sentence Summary
Silicon Dioxide (DB11132) has no recorded original therapeutic indication — it is conventionally used as a pharmaceutical excipient (glidant/anti-caking agent) rather than an active treatment. The TxGNN model predicts it may be effective for Active Peptic Ulcer Disease, but this direction is currently supported only by indirect literature on related silicate compounds (e.g., sucralfate, magnesium trisilicate, orthosilicic acid), with no clinical trials and no direct mechanism-of-action data for DB11132 itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — no therapeutic indication on record; SiO2 is conventionally used as a pharmaceutical excipient |
| Predicted New Indication | Active Peptic Ulcer Disease |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for DB11132. Silicon dioxide is not documented in this evidence pack as an active therapeutic ingredient — it has no listed original indication and is conventionally used in pharmaceutical products as an excipient (glidant, anti-caking, or desiccant agent) rather than as a treatment.
The mechanistic rationale for peptic ulcer disease is therefore indirect. The literature associated with this prediction largely concerns other silicate-class compounds — sucralfate, magnesium trisilicate, orthosilicic acid, and muscovite (a silicate mineral) — which have documented mucosal-protective or acid-buffering properties in gastroesophageal and peptic ulcer disease. These are chemically distinct from synthetic silicon dioxide (DB11132), so the TxGNN association likely reflects a class-level analogy (silicate materials broadly) rather than direct pharmacological evidence for this specific compound.
Given the absence of a defined MOA and the fact that no clinical trial has evaluated DB11132 itself in peptic ulcer disease, this prediction should be regarded as a hypothesis-generating signal rather than an established mechanistic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2986275 | 1985 | RCT | Scand J Gastroenterol | Randomized double-blind trial: sucralfate vs. alginate/antacid in reflux esophagitis; ~70% of patients in both arms symptom-free or improved, 53% healing with sucralfate |
| 6095236 | 1983 | Review | Polimery w medycynie | Review of biological/pharmacological properties of orthosilicic acid and its derivatives |
| 7604597 | 1994 | Review | Likars’ka sprava | Smecta (diosmectite, a silicate clay) normalized gastric aggression/protection ratio and showed acid-neutralizing effect in peptic ulcer patients |
| 2877526 | 1986 | Review | Z Gastroenterol | Overview of medical therapy for reflux esophagitis, including mucosal-coating agents such as sucralfate |
| 1550303 | 1992 | Review | Am Surg | Endoscopic intervention as alternative to surgery for upper GI hemorrhage (relevant to complicated peptic ulcer management) |
| 5458923 | 1970 | Preclinical | Therapie | Anti-inflammatory and gastric anti-ulcerous activity of a steroid alkaloid derivative (paravallarinol) |
| 4615551 | 1974 | Preclinical | Acta Hepatogastroenterol | Effect of amylopectin sulfate on peptic activity of human gastric juice |
US Market Information
Silicon Dioxide (DB11132) has no marketing authorizations on record in this evidence pack (0 licenses, market status: Not marketed). No product table is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on an indirect class-level analogy to other silicate compounds rather than direct evidence for DB11132, there is no clinical trial data, and both the mechanism of action and TFDA-equivalent safety information (warnings/contraindications) are currently missing (Blocking data gap DG001, High-severity gap DG002).
To proceed, the following is needed:
- Confirmed mechanism of action for DB11132 specifically (not analogous silicate compounds)
- Official warnings/contraindications/labeling data to complete an initial safety (S1) assessment
- Preclinical or clinical evidence directly testing DB11132 (rather than sucralfate, diosmectite, or muscovite) in peptic ulcer disease
- Clarification of route of administration and formulation feasibility for a therapeutic (non-excipient) use case
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.